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Abstract
Background: Data are scarce on the comparison of EQ-5D index scores using the UK, US, and
Japan preference weights in other populations. This study was aimed to examine the differences
and agreements between these three weights, psychometric properties including test-retest
reliability, convergent and known-groups validity, and the impact of differences in the EQ-5D
scores on the outcome of cost-utility analysis in Thai people.
Methods: A convenience sample of 303 type 2 diabetic outpatients (18 years or older) from a
cross-sectional study was examined. ANOVA and pos-hoc Bonferroni tests were used to
determine the differences among the three EQ-5D scores. The agreements among the EQ-5D
scores were assessed employing intraclass correlations coefficients (ICCs) and Bland-Altman plots.
The ICCs were utilized to examine the test-retest reliability. Spearman's rho correlation
coefficients were used to assess the convergent validity between the EQ-5D scores and
sociodemographic & clinical data, and health status. Mann-Whitney U tests were used to test the
differences in EQ-5D scores between the known groups including HbA1c level (cut point of 7%),
and the presence of diabetic complications namely neuropathy, retinopathy, nephropathy and
cardiovascular diseases. Seven hypothetical decision trees were created to evaluate the impact of
differences in the EQ-5D scores on the incremental cost-utility ratio (ICUR).
Results: The US weights yielded higher scores than those of the UK and the Japan weights (p <
0.001, both), while the UK and the Japan weighted scores did not differ (p > 0.05). Both UK and
US scores had more agreement with each other than with the Japan scores. Regarding
psychometric properties, the Japan scheme provided better test-retest reliability, convergent and
known-groups validity than both UK and US schemes. The variation in EQ-5D scores estimated
from UK, US, and Japan preference weights had a marginal impact on ICUR (range: 1.23–6.32%).
Conclusion: Since the Japan model showed more preferable psychometric properties than the UK
and the US models and the differences in these EQ-5D scores had a small impact on ICUR, we
recommended that for both clinical and policy purposes the Japan scheme should be used in Thai
people. However, more research needs to be done.
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Background
The health utility (HU) approach to assessing health-
related quality of life (HRQoL) is a commonly used tech-
nique for determining preferences for health outcomes in
evaluation of public health and healthcare interventions
such as cost-utility analyses (CUA) [1,2]. In CUA, a utility
score is assigned to the health state on the cardinal scale
in which dead = 0 and perfect health = 1 to indicate their
preferences for different outcomes. The utility score is
incorporated into quality-adjusted life-year (QALYs)
which combine, in a single index, gains or losses in quan-
tity (life expectancy) and quality of life (HU). The Euro-
QoL (EQ-5D) is the most frequently used HU instrument
for calculating QALYs based on actual measurements of
patients' HRQoL [3].
The EQ-5D instrument consists of a five-item descriptive
system of health states and a visual analog scale (VAS).
Scores for the five health states can be converted into a
utility index score by using scores from value sets (prefer-
ence weights) elicited from a general population. The
best-known preference weights were derived from sam-
ples of the United Kingdom (UK) population which is the
original one for estimating EQ-5D index scores [4]. The
UK-based preference weights are applied to other popula-
tions when country-specific weights are not available.
However, evidence suggests valuations of health states
could differ for people in different countries due to differ-
ences in demographic backgrounds, social-cultural values,
and economic systems [5-8]. Thus, it is advisable to use
country-specific weights in a given country if available.
Unfortunately, preference weights of EQ-5D for Thai peo-
ple are not available yet. Valuation of the EQ-5D health
states nationwide is a complex, time-consuming, and
expensive task, so applying other existing preference
weights is essential if not available in the country. Never-
theless, whose weighting scheme or which cultural/coun-
try-specific populations are appropriate are not known for
Thai population. Besides the UK weights, there are a
number of other countries having their own population-
based preference weights for the EQ-5D [7,9-14]. Of
these, the United States (US) weight scheme is a unique
D1 model [13] different from the UK model (N3 model)
that was applied to other countries' models. Studies have
also shown that EQ-5D scores derived from the US
weights were different from those of the UK [15-17].
Japan has been the first Asian country to develop its own
preference weights of EQ-5D since 2002 [11]. The Japan
model was chosen to represent Asian preference weights.
We were interested in knowing how different EQ-5D
index scores using the UK, US, and Japan preference
weights were. Little was also known about psychometric
properties of these schemes in different cultural contexts
and specific patient samples (all models were developed
in general population). Therefore, we would like to deter-
mine the differences and agreements among these three
countries' preference weighted scores (the three countries
are located in three different continents as well) using a
Thai patient sample. Their psychometric properties
including test-retest reliability, convergent and known-
groups validity were also explored. The psychometric
properties would provide additional evidence of validity
for the use of the EQ-5D index score in Thai settings.
Moreover, we would examine the impact of differences in
the EQ-5D scores on the outcome of CUA employing
hypothetical scenarios.
Methods
Subjects and procedures
The data used in this paper was derived from a cross-sec-
tional study [18]. In this study, a convenience sample of
303 type 2 diabetic outpatients was collected from the
General Police Hospital in Bangkok, Thailand, between
January-June, 2007. Patients with type 2 diabetics waiting
for seeing physicians were approached to participate in
this study. Patients who were eligible for the study were at
least 18 years old and were able to understand the Thai
language. Patients with health problems or cognitive
impairments that could not complete interview were
excluded. The face-to-face interviews include Morisky
Medication Adherence Scale, Center for Epidemiologic
Studies Depression (CES-D), EQ-5D questionnaire, VAS,
sociodemographic and clinical data, together with review-
ing medical records. In addition, about one-fifth of this
sample (N = 64) was randomly selected to conduct one-
two week test-retest reliability via telephone. This study
was approved by the Ethics Committee of the Police Hos-
pital.
EQ-5D: UK, US, and Japan preference weights
The EQ-5D includes a five-item descriptive system, with
one item for each of the following health attributes:
mobility, self care, usual activity, pain/discomfort, and
anxiety/depression. Each attribute has three levels: no
problem, some problem, and major problem. A total of
243 possible health states are generated.
The UK valuation study was conducted based on the
Measuring and Valuation Health (MVH) protocol to col-
lect a general adult population in the United Kingdom
(England, Scotland, and Wales) [4,19]. The preference val-
ues for 42 core health states were elicited using time trade-
off (TTO) methods. The valuations of the 42 health states
were then interpolated by regression models to predict the
index scores for all EQ-5D possible health states. The UK
model consists of a set of variables representing each EQ-
5D health dimension, with two dummy variables repre-
senting the levels of each dimension. A dichotomous var-Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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iable (N3) was also added to the model to indicate if level
3 (major problem) occurs within at least one dimension.
The US health state valuation study was derived based on
the UK MVH protocol. But the US algorithm replaced the
N3 variable by D1, which represents additional number
of dimensions at level 2 and 3 beyond the first [13].
The Japan valuation study is a quasi-replication of the UK
MVH protocol using the modified protocol, where each
respondent was presented with 17 health states, instead of
42 health states. The plain main effects model was pre-
ferred [11].
Data analysis
The EQ-5D index scores were calculated using the UK, US,
and Japan preference weights. We first determined the dif-
ferences among the three index scores using ANOVA, fol-
lowed by pos-hoc Bonferroni tests. The agreements
among the EQ-5D scores using the UK, US, and Japan
preference weights were also assessed employing intrac-
lass correlations coefficients (ICCs) and Bland-Altman
plots [20]. We then examined the psychometric properties
of these EQ-5D scores using the following approaches:
one-two week test-retest reliability, convergent validity
and known-groups validity [21].
To evaluate the test-retest reliability, intraclass correla-
tions coefficients (ICCs) were employed. For convergent
validity, we assessed the associations between the three
EQ-5D scores and sociodemographic & clinical data and
health status including age, gender, income, duration of
diabetes, body mass index (an indicator of obesity),
HbA1c level, number of diabetic complications, CES-D
scores, and VAS scores using Spearman's rho correlation
coefficients.
Concerning known-groups validity, we examined the abil-
ity of the three EQ-5D scores using the UK, US, and Japan
preference weights to discriminate between clinical
known groups including HbA1c level (below versus equal
or above 7%), and presence and absence of diabetic com-
plications namely neuropathy, retinopathy, nephropathy
and cardiovascular. Mann-Whitney U tests were used to
test the differences in EQ-5D index scores between these
known groups because the distributions of EQ-5D utility
scores had a number of outliers. All analyses were per-
formed using SPSS version 13.0.
To evaluate the impact of the differences in EQ-5D index
scores using UK, US, and Japan preference weights on
CUA, seven hypothetical decision trees were created. We
compared a new drug (Drug A) with an existing drug
(Drug B). The details of each data component of the base-
case scenario (decision tree 1) are presented in Table 1.
We also created decision trees 2–7 which overestimated
the base-case utility scores by mean and median differ-
ences in EQ-5D index scores between three pairs of pref-
erence weights: UK versus US, UK versus Japan, and US
versus Japan, respectively. We computed the incremental
cost-utility ratio (ICUR) which is equal to the ratio of
incremental costs (cost of drug A minus cost of drug B)
over incremental QALY (QALY of drug A minus QALY of
drug B).
Results
The sociodemographic and clinical characteristics are
shown in Table 2. The mean age was 61.6 years old (SD:
11.4; range: 27–90) and 71% were female. The median of
income was 5,000 Baht/month (interquartile: 0–16,300)
(34 Baht ≈ 1 US$). The mean HbA1c, mean BMI (body
mass index), and mean duration of diabetes (told by the
patients) were 7.7% (SD: 1.7; range: 4.0–15.8) and 26.7
Kg/m2 (SD: 1.7; range: 16.7–55.2), and 12.2 years (SD:
8.4; range: 0–50), respectively. Regarding diabetic compli-
cations, there were 124 cases (40.9%) of neuropathy, 51
(16.8%) of retinopathy, 25 (8.3%) of nephropathy, and
44 (14.5%) of cardiovascular disorders. The median CES-
D scores were 5 (interquartile: 2–10). The mean VAS
scores were 0.69 (SD: 0.16; range: 0.10–1.00).
The distributions of EQ-5D scores derived from the UK,
US, and Japan preference weights were skewed to the left
(Figure 1). The mean (95% CI) EQ-5D scores were as fol-
lows: UK weights, 0.76 (0.74–0.78); US weights, 0.81
(0.80–0.83); and Japan weights, 0.75 (0.73–0.76) (Table
3). The three mean scores were significantly different
across methods (ANOVA, p < 0.001). Post-hoc Bonferroni
Table 1: Data component of the base-case scenario (decision tree 1)
Drug A (new drug) Drug B (existing drug)
Success Failure Success Failure
Probability of treatment results 0.6 0.4 0.5 0.5
Survival (year) 10 5 8 4
Utility scores 0.9 0.5 0.8 0.4
Cost (Baht) 100,000 50,000 80,000 40,000Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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tests found that the EQ-5D scores using US weights were
significantly higher than those derived from the UK and
Japan weights (both, p < 0.001). The mean EQ-5D scores
using UK and Japan weights, however, did not signifi-
cantly differ from each other (p = 0.68). Medians (inter-
quartile) of the EQ-5D scores from the UK, US, and Japan
preference weights were 0.78 (0.69–0.86), 0.83 (0.76–
0.85), and 0.73 (0.65–0.79), respectively. The EQ-5D
scores using the UK weights yielded the largest range (-
0.21–1.00), whereas those scores derived from US and
Japan preference weights had similar range (0.06–1.00
and 0.08–1.00, respectively).
Table 4 presents the estimated mean (95% CI) differences
of EQ-5D scores for the UK/US, UK/Japan, and US/Japan
schemes were -0.05 (-0.06-(-0.04)), 0.02 (0.01–0.03),
and 0.07 (0.06–0.07), respectively. Medians (interquar-
tile) were -0.04 (-0.09–0.00), 0.03 (0.00–0.07), and 0.08
(0.00–0.12) for the UK/US, UK/Japan, and US/Japan
weights, respectively. Reported clinically important differ-
ence (CID) for the EQ-5D is 0.074 [22]. The median dif-
ference between US and Japan weights (0.08) was slightly
higher than the CID of 0.074.
Agreement between the EQ-5D index scores using UK, US, 
and Japan preference weights
Table 5 illustrates the agreement between EQ-5D values
derived from UK, US, and Japan preference weights using
ICCs. The ICCs were very high between the pairs of these
three approaches, with the highest ICC of 0.97 between
UK versus US methods, followed by the ICCs of US versus
Japan (0.95) and of UK versus Japan (0.93), respectively.
Bland-Altman Plots
Bland-Altman plots were created to compare the agree-
ment among the three EQ-5D scores (Figures 2A–C).
These plots showed the differences between scores (Y-
axis) and the means of scores (X-axis). The mean of the
differences (d) and the limits of agreement were indicated
by dotted lines. The 95% limits of agreement were
obtained by using the following formula [20]: d ±
1.96*SD of d.
The Bland-Altman plot of UK and US weights showed that
96.4% of the difference scores were between the limits of
agreement, 3.3% below the lower agreement line, and
0.3% above the upper agreement line (Figures 2A).
Approximately 64% of the UK weights were lower than
the US weights (less than zero), 31% are equal, and 5%
are higher (greater than zero).
Table 2: Characteristics of type 2 diabetic patients (N = 303)
Characteristics Value
Age (year) Mean ± SD 61.1 ± 11.4
Range 27–90
Gender Female 71%
Income (Baht per month) Median (25th percentile, 75th percentile) 5,000 (0, 16,300)
Duration of diabetes (year) Mean ± SD 12.2 ± 8.4
Range 0–50
HbA1c level Mean ± SD 7.7 ± 1.7%
Range 4.0–15.8%
Body mass index (Kg/m2) Mean ± SD 26.7 ± 1.7
Range 16.7–55.2
Diabetic complication Neuropathy 124 (40.9%)
Retinopathy 51 (16.8%)
Nephropathy 25 (8.3%)
Cardiovascular disorders 44 (14.5%)
CES-D scores Median (25th percentile, 75th percentile) 5 (2, 10)
VAS scores (usual scores: 0–1) Mean ± SD 0.69 ± 0.16
Range 0.10–1.00
Table 3: Descriptive statistics of EQ-5D index scores using the UK, US, and Japan preference weights
Preference weights Mean 95% CI Median Q25 Q75 Range
UK 0.76 0.74–0.78 0.78 0.69 0.86 -0.21–1.00
US 0.81 0.80–0.83 0.83 0.76 0.85 0.06–1.00
Japan 0.75 0.73–0.76 0.73 0.65 0.79 0.08–1.00Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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The Bland-Altman plot of UK and Japan weights showed
that 96% of the difference scores were between the limits
of agreement, 4% below the lower agreement line, and
none of the scores above the upper agreement line (Fig-
ures 2B). Approximately 64% of the UK weights were
higher than the Japan weights (greater than zero), 21% are
equal, and 15% are lower (less than zero).
The Bland-Altman plot of US and Japan weights showed
that 96.4% of the difference scores were between the lim-
its of agreement, 3.6% below the lower agreement line,
and none above the upper agreement line (Figures 2C).
Approximately 75% of the US weights were higher than
the Japan weights (greater than zero), 21% are equal, and
4% are lower (less than zero).
Test-retest reliability
The one-two week test-retest reliability of EQ-5D index
scores using UK, US, and Japan preference weights (N =
64) is presented in Table 6. It was found that the Japan
schemes provided the highest ICCs (0.78) among the
three schemes, while the UK and US weights had the same
ICCs of 0.74. Rosner suggests that ICC < 0.40 indicates
poor agreement, 0.40 ≤ ICC < 0.75 indicates fair to good
agreement, and ICC ≥ 0.75 indicates excellent agreement
[23]. Based on this criterion, the Japan weights had excel-
lent agreement, whereas both UK and US weights had
good agreement on test-retest reliability. It should be
noted that in this study the test-retest reliability was con-
ducted via telephone interview whose test-retest correla-
tions were generally lower than those by face-to-face
interview [24]. If the test-retest via face-to-face interview
had been done, the ICCs of the three approaches should
have been increased. Thus, the UK and the US weights
might have excellent agreement on test-retest reliability.
However, this would not affect the results that the Japan
scheme yielded the highest ICC because all three prefer-
ence weights would have higher ICCs.
Convergent validity
EQ-5D scores derived from UK, US, and Japan preference
weights were significantly associated with all sociodemo-
graphic, clinical, and health status variables except for age
(Table 7). Spearman's rho correlation coefficients range -
0.14 to -0.50. Based on Colton's criteria [25], EQ-5D
scores had a little to medium correlation with these varia-
bles. However, most magnitudes of correlation between
the Japan weighted scores and these variables were higher
than those between both UK and US weighted scores and
these factors. The magnitudes of correlation between the
UK and the US weights and all variables were quite simi-
lar.
Known-groups validity
Among the three weighting schemes, the Japan weights
obviously showed better discriminant validity than both
Distribution of EQ-5D scores derived from the UK, US, and Japan preference weights Figure 1
Distribution of EQ-5D scores derived from the UK, US, and Japan preference weights.
 
Table 4: Descriptive statistics of differences in EQ-5D index scores using the UK, US, and Japan preference weights
Mean 95% CI Median Q25 Q75 Range
UK/US -0.05* -0.06-(-0.04) -0.04 -0.09 0.00 -0.35-0.13
UK/Japan 0.02 0.01-0.03 0.03 0.00 0.07 -0.51-0.15
US/Japan 0.07* 0.06-0.07 0.08 0.00 0.12 -0.22-0.13
* p < 0.01Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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UK and US weights for all known groups including HbA1c
level (above and below 7%) and diabetic complications
(presence and absence) namely neuropathy, retinopathy,
nephropathy and cardiovascular diseases (Table 8). The
relative precision values suggest that the Japan weights
discriminated more efficiently than the UK and US
weights (the ratios of Japan versus UK and Japan versus
US greater than 1.00). Between the UK and US weights,
the UK weighted discriminated better for the presence and
absence of neuropathy, retinopathy, and cardiovascular
complications (the ratios of UK versus US greater than
1.00), whereas, the US weights did more efficiently for
HbA1c level and the presence and absence of nephropa-
thy (the ratios of UK versus US less than 1.00).
The impact of the differences in EQ-5D index scores using 
UK, US, and Japan preference weights on cost-utility 
analysis
As shown in Table 9, the incremental cost of drug A over
drug B was 300,000 Baht for all scenarios. In the base-case
scenario, the incremental QALY of using drug A over drug
B was 2.4, thus providing an ICUR of 125,000 Baht/
QALY. The ICUR for all alternative decision trees ranged
from 117,096 Baht/QALY (6.32% difference from the
base case) to 123,457 Baht/QALY (1.23% difference from
the base case). The seventh decision tree that had the larg-
est percent difference in ICUR from the base case was the
scenario using the median difference between US and
Japan weights, while the third decision tree that had the
smallest percent difference in ICUR from the base case
was the scenario employing the mean difference between
UK and Japan weights.
Discussion
To the best of our knowledge, this is the first study exam-
ining the differences and cross-cultural validation
between EQ-5D scores derived from UK, US, and Japan
preference weights. The results showed that there were sig-
nificant differences across the three EQ-5D index scores.
US weights yielded higher scores than those of UK and
Japan weights (p < 0.001, both), while the UK and Japan
weighted scores did not differ (p > 0.05). The EQ-5D index
scores derived from both UK and Japan weights were also
comparable to that of a previous study which showed that
type 2 diabetes provided the mean EQ-5D score of 0.75
[26]. Both UK and US scores had more agreement with
each other than with the Japan scores. As for psychometric
properties, the Japan scheme provided better test-retest
reliability, convergent and known-groups validity than
both UK and US schemes. We also determined the impact
of the differences in these EQ-5D index scores on the out-
come of CUA. It was found that variation in utility scores
estimated from UK, US, and Japan preference weights had
a relatively small impact on CUA (range: 1.23–6.32%).
Our study showed that the US weighted scores were
higher than the UK weighted scores. This result is consist-
ent with the previous study conducted in US patients liv-
ing with HIV infection [17]. However, our study yielded
larger mean difference scores (mean difference = 0.05)
than those of the previous study (mean difference = 0.03).
This may be due to differences in health states of patient
populations. Johnson et al found that the discrepancy
between the US and UK schemes was smaller for better
health states, but larger for extreme health problems [15].
Table 5: Agreement between UK, US, and Japan weights
Preference weights ICC (95% CI)
UK & US 0.97** (0.96–0.97)
UK & Japan 0.93** (0.92–0.95)
US & Japan 0.95**(0.94–0.96)
* p < 0.01, **p < 0.001
The Bland-Altman plots of EQ-5D scores derived from the UK, US, and Japan preference weights Figure 2
The Bland-Altman plots of EQ-5D scores derived from the UK, US, and Japan preference weights.
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This finding is also similar to our study (please see Figure
2A). In the previous US study, the HIV patients had better
health (mean EQ-5D scores using US and UK was 0.87
and 0.84, respectively) than those of the diabetic patients
in the present study (mean EQ-5D scores using US and
UK was 0.81 and 0.76, respectively). Therefore, this may
be the reason why the larger mean difference between US
and UK was found in the present study.
This study also showed that the EQ-5D index scores using
the US scheme were higher than those of the Japan
scheme with the estimated mean difference of 0.07, while
the UK model yielded slightly higher scores than the
Japan model with the mean difference of 0.02 (not statis-
tically significant). No previous study has compared
between US and Japan weighted scores; however, the large
discrepancy may be attributable to differences in algo-
rithms, cultures, research methods, and/or other factors.
Tsuchiya and colleagues have reported that the Japan
scheme yielded consistently higher scores than the UK
weights except for the very mild states [11]. This finding
contrasted with our results that the mean UK weighted
scores had slightly higher than the mean Japan index
scores but they were not significantly different. Also, the
Bland-Altman plot (Figure 2B) presented that the majority
of the UK weighted scores (62%) was higher than the
Japan weights except for the extreme health states. These
different results may be due to the fact that they did the
previous study in a general population, but we used a real
patient population. The utility weights derived from a het-
erogeneous general population and applied to a patient
population may be less precise to detect differences across
cultures. In addition, due to differences in population rat-
ings and healthcare settings between Japan and Thailand,
EQ-5D valuations would perform differently when
applied to different populations.
It is not surprising that UK and US preference weights had
more agreement with each other than with Japan weights
because they are western countries whose cultures are dif-
ferent from that of Japan which is in Asia. Moreover, the
Japan scheme provided better test-retest reliability, con-
vergent and known-groups validity than both UK and US
schemes in this Thai sample. These results may reflect the
fact that Thailand is an Asian country whose culture is
closer to Japan than to both UK and US. Thus, it is more
likely that the Japan weights should be used for EQ-5D
valuations for Thai people than the UK or US weights.
Even though our results showed that there was difference
in EQ-5D scores derived from the UK, US and Japan
weights, the impact on ICUR was marginal. This leads to
the question of which preference weights should be used
and in what situations. All of our results suggest that if the
EQ-5D index scores is used as a HRQoL measure for the
purpose of clinical decision making such as using the util-
ity scores to be a clinical indicator to monitor patients'
health status, the Japan should be applied for Thais. How-
ever, if one would like to evaluate CUA or CEA whose out-
comes are QALYs gained, the choice of weighting scheme
does not matter. Nevertheless, if we have to recommend a
method, the Japan should be the most appropriate one
because they demonstrated better psychometric proper-
ties than the UK and US weights.
The results of this study need to be interpreted in the light
of these following limitations. First, we used only cross-
sectional data. Differences in change scores may be likely
to have a greater impact on ICUR than changes in absolute
scores. Thus, further study should be done in longitudinal
data. Second, our data were derived from diabetic outpa-
tients, so the results were limited to a specific patient
group. The findings are not likely to be able to be general-
ized to other patient populations. Other clinical popula-
tions need investigation. Finally, we utilized a simple
hypothetical decision tree model to examine the impact of
variability in EQ-5D index scores on ICUR. Therefore,
using real CUA data should be more informative.
Table 6: One-two week test-retest reliability of EQ-5D index 
scores using UK, US, and Japan preference weights (N = 64)
Preference weights ICC (95% CI)
UK 0.74** (0.57–0.84)
US 0.74** (0.57–0.84)
Japan 0.78** (0.63–0.86)
* p < 0.01, **p < 0.001
Table 7: Convergent validity of EQ-5D index scores using UK, 
US, and Japan preference weights
Variables UK US Japan
Age (year) -0.15a -0.02 -0.04
Gender (0 = male, 1 female) -0.25** -0.25** -0.25**
Income (Baht/month) 0.17** 0.17** 0.19**
Duration of diabetes (year) -0.14* -0.15* -0.14*
Body mass index (Kg/m2) -0.15** -0.15** -0.19**
HbA1c level (%) -0.17** -0.17** -0.20**
Number of diabetic complications -0.40** 0.40** -0.43**
CES-D scores† -0.49** -0.49** -0.50**
VAS scores§ 0.46** 0.46** 0.48**
a The number in cells is Spearman's rho correlation coefficients 
between sociodemographic, clinical, and health status variables.
†Higher scores indicate more depressive symptoms.
§Higher scores indicate better health.
* p < 0.05, **p < 0.01Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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Table 8: Known-groups validity of the EQ-5D index scores using UK, US, and Japan preference weights
No. UK US Japan Relative Precisiona Relative Precisionb Relative Precisionc
HbA1c < 7% 110 0.79 0.83 0.77
HbA1c ≤ 7% 193 0.75 0.80 0.73
Difference 0.04 0.03* 0.04*
Z statistic -1.91 -2.00 -2.59 0.96 1.36 1.30
Neuropathy (No) 179 0.81 0.84 0.79
Neuropathy (Yes) 124 0.69 0.77 0.69
Difference 0.12** 0.07** 0.10**
Z statistic -5.94 -5.89 -6.33 1.01 1.06 1.07
Retinopathy (No) 252 0.78 0.82 0.76
Retinopathy (Yes) 51 0.69 0.76 0.69
Difference 0.09* 0.06* 0.07**
Z statistic -2.16 -2.07 -2.68 1.04 1.24 1.29
Nephropathy (No) 278 0.77 0.82 0.75
Nephropathy (Yes) 25 0.67 0.75 0.68
Difference 0.10* 0.07** 0.07**
Z statistic -2.57 -2.70 -2.75 0.95 1.07 1.02
Cardiovascular (No) 259 0.78 0.83 0.76
Cardiovascular Yes) 44 0.65 0.73 0.66
Difference 0.13** 0.10** 0.10**
Z statistic -3.48 -3.45 -3.60 1.01 1.03 1.04
Note: Data in the columns of UK, US, and Japan are mean EQ-5D index scores. The differences in the scores between groups were tested by 
Mann-Whitney U tests.
* p-value < 0.05, **p-value < 0.01
a Ratio of Z statistics for UK weights & US weights
b Ratio of Z statistics for Japan weights & UK weights
c Ratio of Z statistics for Japan weights & US weights
Table 9: Impact of differences in EQ-5D index scores using UK, US, and Japan preference weights on ICUR for 7 hypothetical decision 
trees
Variables Hypothetical decision tree
1234567
EQ-5D index scores when the drug was effective (success)
Drug A 0.900 0.951 0.916 0.967 0.935 0.928 0.981
Drug B 0.800 0.851 0.816 0.867 0.835 0.828 0.881
EQ-5D index scores when the drug was not effective (failure)
Drug A 0.500 0.551 0.516 0.567 0.535 0.528 0.581
Drug B 0.400 0.451 0.416 0.467 0.435 0.428 0.481
QALY
Drug A 6.40 6.81 6.53 6.94 6.68 6.62 7.05
Drug B 4.00 4.31 4.10 4.40 4.21 4.17 4.49
Incremental cost (Baht) 300,000 300,000 300,000 300,000 300,000 300,000 300,000
Incremental QALY 2.40 2.50 2.43 2.54 2.47 2.45 2.56
ICUR (Baht/QALY) 125,000 119,904 123,457 118,110 121,457 122,150 117,096
% Difference in ICUR from base case (Decision tree 1) - 4.08 1.23 5.51 2.83 2.28 6.32
Decision tree 1 represents the base-case scenario, while decision trees 2–7 mean the scenarios where base-case utility scores overestimated by 
0.051 (mean difference between UK versus US weights), 0.016 (mean difference between UK versus Japan weights), 0.067 (mean difference 
between US versus Japan weights), 0.035 (median difference between UK versus US weights), 0.028 (median difference between UK versus Japan 
weights), and 0.081 (median difference between US versus Japan weights).Health and Quality of Life Outcomes 2008, 6:71 http://www.hqlo.com/content/6/1/71
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Conclusion
In this study, we compared weights on EQ-5D valuations
using algorithms developed in the UK, US, and Japan gen-
eral populations, but cross-validated using a Thai patient
sample. Our results suggest that the US scheme provided
higher EQ-5D index scores than the UK and Japan
schemes, while the UK and Japan weighted scores did not
significantly differ. However, the impact of the differences
in these EQ-5D index scores on the outcome of CUA was
quite small. Both UK and US scores had more agreement
with each other than with Japan scores. The Japan scheme
provided better test-retest reliability, convergent and
known-groups validity than both UK and US schemes. We
recommended that among these three weights the Japan
model should be used in Thai people. However, more
research needs to be done.
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